



2024 Complex General Surgical Oncology

All References



Below you will find the topics and their accompanying references for the 2024 Complex General Surgical Oncology Continuous Certification Assessment. **Diplomates are neither required nor expected to read all of these references before or during the completion of the assessment.** The Key References are marked with a yellow star ★ below.

Due to limited permissions, we cannot provide full-text links and article PDFs on this reference document, as it is not hosted on a secure browser. Article links on this document will take you to the journal page on PubMed.

To view full-text articles prior to opening your assessment, please log in to the [surgeon portal](#). Article links/PDFs will be freely available on the surgeon portal beginning on **August 26, 2024**. Additionally, while you are completing your assessment on the exam platform, full-text links/PDFs will be available for all Key and Additional References.

Anaplastic Large Cell Lymphoma

- ★ [Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J.* 2017;37\(3\):285-289. doi:10.1093/asj/sjw259](#)

Biliary Tract Cancer

- [Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. *J Clin Oncol.* 2022;40\(18\):2048-2057. doi:10.1200/JCO.21.02568](#)
- ★ [Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer \(BILCAP\): a randomised, controlled, multicentre, phase 3 study. *Lancet Oncol.* 2019;20\(5\):663-673. doi:10.1016/S1470-2045\(18\)30915-X](#)

Breast Cancer

- [Chakrabarti D, Verma M, Kukreja D, Shukla M, Bhatt MLB. Palliative chest wall radiotherapy for a fungating and bleeding metastatic breast cancer: quality of life beyond cure. *BMJ Case Rep.* 2021;14\(8\):e243722. doi:10.1136/bcr-2021-243722](#)
- Consensus Guideline on Breast Cancer Lumpectomy Margins. American Society of Breast Surgeons. Published 2018. Accessed May 10, 2024. <https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Breast-Cancer-Lumpectomy-Margins.pdf>



2024 Complex General Surgical Oncology

All References



- ★ [Grewal AS, Freedman GM, Jones JA, Taunk NK. Hypofractionated radiation therapy for durable palliative treatment of bleeding, fungating breast cancers. *Pract Radiat Oncol.* 2019;9\(2\):73-76. doi:10.1016/j.prro.2018.11.003](#)
- [Jacobson G, Kaidar-Person O, Haisraely O, et al. Palliative radiation therapy for symptomatic advanced breast cancer. *Sci Rep.* 2021;11\(1\):5282. doi:10.1038/s41598-021-84872-9](#)
- ★ [Salibian AA, Olson B, Shauly O, Patel KM. Oncoplastic breast reconstruction: principles, current techniques, and future directions. *J Surg Oncol.* 2022;126\(3\):450-459. doi:10.1002/jso.26897](#)
- ★ [Schmid P, Cortes J, Puztai L, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med.* 2020;382\(9\):810-821. doi:10.1056/NEJMoa1910549](#)
- ★ [Wilson PC, Chagpar AB, Cicek AF, et al. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. *Breast J.* 2018;24\(6\):976-980. doi:10.1111/tbj.13117](#)

Clinical Trials

- ★ [Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. *J Clin Oncol.* 2004;22\(4\):730-734. doi:10.1200/JCO.2004.03.160](#)
- [Diehl KM, Green EM, Weinberg A, et al. Features associated with successful recruitment of diverse patients onto cancer clinical trials: report from the American College of Surgeons Oncology Group. *Ann Surg Oncol.* 2011;18\(13\):3544-3550. doi:10.1245/s10434-011-1818-9](#)

Colorectal Cancer

- [Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer \(SCOT\): an international, randomised, phase 3, non-inferiority trial. *Lancet Oncol.* 2018;19\(4\):562-578. doi:10.1016/S1470-2045\(18\)30093-7](#)
- ★ [Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. *Cancer.* 2015;121\(4\):527-534. doi:10.1002/cncr.29072](#)

Cortical Neoplasms

- ★ [Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2021;19\(7\):839-868. doi:10.6004/jnccn.2021.0032](#)



2024 Complex General Surgical Oncology

All References



Delirium Screening

- ★ [Malik U, Alam Z, Loucks A, et al. Downstream consequences of abnormal cognitive screening in older adults seen pretreatment in a geriatric oncology clinic. *J Geriatr Oncol.* 2020;11\(5\):784-789. doi:10.1016/j.jgo.2019.10.022](#)

Fibromatosis (Desmoid) Tumors

- [Anneberg M, Svane HML, Fryzek J, et al. The epidemiology of desmoid tumors in Denmark. *Cancer Epidemiol.* 2022;77:102114. doi:10.1016/j.canep.2022.102114](#)
- [Fiore M, Coppola S, Cannell AJ, et al. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. *Ann Surg.* 2014;259\(5\):973-978. doi:10.1097/SLA.0000000000000224](#)
- ★ [Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a \$\gamma\$ -secretase inhibitor for desmoid tumors. *N Engl J Med.* 2023;388\(10\):898-912. doi:10.1056/NEJMoa2210140](#)
- [Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet \(SPAEN\) and European Organization for Research and Treatment of Cancer \(EORTC\)/Soft Tissue and Bone Sarcoma Group \(STBSG\). *Ann Oncol.* 2017;28\(10\):2399-2408.](#)

Gastric Cancer

- ★ [Vos EL, Nakauchi M, Gönen M, et al. Risk of lymph node metastasis in T1b gastric cancer: an international comprehensive analysis from the Global Gastric Group \(G3\) Alliance. *Ann Surg.* 2023;277\(2\):e339-e345. doi:10.1097/SLA.00000000000005332](#)
- ★ [Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. *JAMA Surg.* 2021;156\(8\):721-729. doi:10.1001/jamasurg.2021.2373](#)
- [Zhao B, Zhang J, Zhang J, et al. Risk factors associated with lymph node metastasis for early gastric cancer patients who underwent non-curative endoscopic resection: a systematic review and meta-analysis. *J Gastrointest Surg.* 2019;23\(7\):1318-1328. doi:10.1007/s11605-018-3924-5](#)

Gastrointestinal Obstruction – Malignant

- [Krouse RS, Anderson GL, Arnold KB, et al. Surgical versus non-surgical management for patients with malignant bowel obstruction \(S1316\): a pragmatic comparative effectiveness trial. *Lancet Gastroenterol Hepatol.* 2023;8\(10\):908-918. doi:10.1016/S2468-1253\(23\)00191-7](#)



2024 Complex General Surgical Oncology

All References



- [Pujara D, Chiang YJ, Cormier JN, Bruera E, Badgwell B. Selective approach for patients with advanced malignancy and gastrointestinal obstruction. *J Am Coll Surg.* 2017;225\(1\):53-59. doi:10.1016/j.jamcollsurg.2017.04.033](#)

Gastrointestinal Stromal Tumors

- ★ [Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFR \$\alpha\$ wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. *JAMA Oncol.* 2016;2\(7\):922-928. doi:10.1001/jamaoncol.2016.0256](#)
- [Burgoyne AM, De Siena M, Alkhuziem M, et al. Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and notch pathway mutations. *JCO Precis Oncol.* 2017;2017:PO.17.00014. doi:10.1200/PO.17.00014](#)
- [Catalano F, Cremante M, Dalmasso B, et al. Molecular tailored therapeutic options for advanced gastrointestinal stromal tumors \(GISTs\): current practice and future perspectives. *Cancers \(Basel\).* 2023;15\(7\):2074. doi:10.3390/cancers15072074](#)
- [Neppala P, Banerjee S, Fanta PT, et al. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. *Cancer Metastasis Rev.* 2019;38\(3\):525-535. doi:10.1007/s10555-019-09818-0](#)
- ★ [von Mehren M, Kane JM, Riedel RF, et al. NCCN Guidelines[®] insights: gastrointestinal stromal tumors, version 2.2022. *J Natl Compr Canc Netw.* 2022;20\(11\):1204-1214. doi:10.6004/jnccn.2022.0058](#)

Hepatocellular Carcinoma

- ★ [Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol.* 2022;76\(4\):862-873. doi:10.1016/j.jhep.2021.11.030](#)
- ★ [Julien C, Le-Bail B, Ouazzani Touhami K, et al. Hepatocellular adenoma risk factors of hemorrhage: size is not the only concern!: single-center retrospective experience of 261 patients. *Ann Surg.* 2021;274\(5\):843-850. doi:10.1097/SLA.00000000000005108](#)
- [Krause K, Tanabe KK. A shifting paradigm in diagnosis and management of hepatic adenoma. *Ann Surg Oncol.* 2020;27\(9\):3330-3338. doi:10.1245/s10434-020-08580-w](#)
- [Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. *JAMA Oncol.* 2020;6\(12\):e204930. doi:10.1001/jamaoncol.2020.4930](#)



2024 Complex General Surgical Oncology

All References



Intraductal Papillary Mucinous Neoplasm

- [Nikiforova MN, Wald AI, Spagnolo DM, et al. A combined DNA/RNA-based next-generation sequencing platform to improve the classification of pancreatic cysts and early detection of pancreatic cancer arising from pancreatic cysts. *Ann Surg.* 2023;278\(4\):e789-e797. doi:10.1097/SLA.0000000000005904](#)
- ★ [Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. *Pancreatology.* 2024;24\(2\):255-270. doi:10.1016/j.pan.2023.12.009](#)
- [Wilson GC, Maithel SK, Bentrem D, et al. Are the current guidelines for the surgical management of intraductal papillary mucinous neoplasms of the pancreas adequate? a multi-institutional study. *J Am Coll Surg.* 2017;224\(4\):461-469. doi:10.1016/j.jamcollsurg.2016.12.031](#)

Low-grade Appendiceal Mucinous Neoplasm

- ★ [Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. *J Am Coll Surg.* 2018;226\(4\):434-443. doi:10.1016/j.jamcollsurg.2017.12.027](#)

Melanoma

- [Blank CU, Reijers ILM, Pennington T, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab \(IPI\) and nivolumab \(NIVO\) in resectable stage III melanoma. *J Clin Oncol.* 2020;38\(15\):10002-10002. doi:10.1200/JCO.2020.38.15_suppl.10002](#)
- [Blank CU, Reijers ILM, Saw RPM, et al. Survival data of PRADO: a phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab \(IPI\) and nivolumab \(NIVO\) in resectable stage III melanoma. *J Clin Oncol.* 2022;40\(16\):9501-9501. doi:10.1200/JCO.2022.40.16_suppl.9501](#)
- FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. US Food and Drug Administration. Published February 16, 2024. Accessed May 24, 2024 <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma>
- [Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N Engl J Med.* 2023;388\(9\):813-823. doi:10.1056/NEJMoa2211437](#)
- ★ [Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma \(OpACIN-neo\):](#)



2024 Complex General Surgical Oncology

All References



[a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol.* 2019;20\(7\):948-960. doi:10.1016/S1470-2045\(19\)30151-2](#)

- [Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. *J Clin Oncol.* 2021;39\(24\):2656-2666. doi:10.1200/JCO.21.00612](#)
- ★ [Wermke M, Chesney J, Whitman E, et al. Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte \(TIL\) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144-01 study. *Ann Oncol.* 2023;34\(suppl 2\):100589. doi:10.1016/iotech/iotech100589](#)

Melanoma – Ocular

- FDA approves melphalan as a liver-directed treatment for uveal melanoma. US Food and Drug Administration. Published August 15, 2023. Accessed May 10, 2024. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-melphalan-liver-directed-treatment-uveal-melanoma>
- ★ [Zager JS, Orloff MA, Ferrucci PF, et al. FOCUS phase 3 trial results: percutaneous hepatic perfusion \(PHP\) with melphalan for patients with ocular melanoma liver metastases \(PHP-OCM-301/301A\). *J Clin Oncol.* 2022;40\(16\):9510-9510. doi:10.1200/JCO.2022.40.16_suppl.9510](#)

Merkel Cell Carcinoma

- ★ [Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial. *J Clin Oncol.* 2020;38\(22\):2476-2487. doi:10.1200/JCO.20.00201](#)

Palliation

- [Agarwal R, Epstein AS. The role of palliative care in oncology. *Semin Intervent Radiol.* 2017;34\(4\):307-312. doi:10.1055/s-0037-1608702](#)
- ★ [Bajwah S, Oluyase AO, Yi D, et al. The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers. *Cochrane Database Syst Rev.* 2020;9\(9\):CD012780. doi:10.1002/14651858.CD012780.pub2](#)
- ★ [Blumenthaler AN, Bruera E, Badgwell BD. Palliative and supportive care consultation for patients with malignant gastrointestinal obstruction is associated with broad interdisciplinary management. *Ann Surg.* 2023;277\(2\):284-290. doi:10.1097/SLA.0000000000004974](#)
- [Gouldthorpe C, Power J, Taylor A, Davies A. Specialist palliative care for patients with cancer: more than end-of-life care. *Cancers \(Basel\).* 2023;15\(14\):3551. doi:10.3390/cancers15143551](#)



2024 Complex General Surgical Oncology

All References



Palpable Nodal Disease

- ★ [Reijers ILM, Rawson RV, Colebatch AJ, et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. *JAMA Surg.* 2022;157\(4\):335-342. doi:10.1001/jamasurg.2021.7554](#)

Pancreas Adenocarcinoma

- ★ [Boulay BR, Parepally M. Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. *World J Gastroenterol.* 2014;20\(28\):9345-9353. doi:10.3748/wjg.v20.i28.9345](#)
- ★ [Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med.* 2018;379\(25\):2395-2406. doi:10.1056/NEJMoa1809775](#)
- [Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. *Arch Surg.* 1985;120\(8\):899-903. doi:10.1001/archsurg.1985.01390320023003](#)
- ★ [Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. *JAMA Oncol.* 2022;8\(9\):1263-1270. doi:10.1001/jamaoncol.2022.2319](#)
- [Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer \(ESPAC-4\): a multicentre, open-label, randomised, phase 3 trial. *Lancet.* 2017;389\(10073\):1011-1024. doi:10.1016/S0140-6736\(16\)32409-6](#)
- [Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA.* 2007;297\(3\):267-277. doi:10.1001/jama.297.3.267](#)
- ★ [Tempero MA, Pelzer U, O'Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. *J Clin Oncol.* 2023;41\(11\):2007-2019. doi:10.1200/JCO.22.01134](#)

Perianal Neoplasms

- ★ [Thompson HM, Kim JK. Perianal Paget's disease. *Dis Colon Rectum.* 2021;64\(5\):511-515. doi:10.1097/DCR.0000000000002000](#)



2024 Complex General Surgical Oncology

All References



Quality Improvement

- Plan-Do-Study-Act Worksheet, Directions, and Examples. Agency for Healthcare Research and Quality. February 2015. Updated March 2024. Accessed March 18, 2024. <https://www.ahrq.gov/health-literacy/improve/precautions/tool2b.html>
- ★ [Senter L, Veney D, Surplus T, et al. Patient understanding of tumor genomic testing: a quality improvement effort. *JCO Oncol Pract.* 2023;19\(1\):e8-e14. doi:10.1200/OP.22.00316.](#)

Rectal Adenocarcinoma

- ★ [Cotti GC, Pandini RV, Braghiroli OFM, et al. Outcomes of patients with local regrowth after nonoperative management of rectal cancer after neoadjuvant chemoradiotherapy. *Dis Colon Rectum.* 2022;65\(3\):333-339. doi:10.1097/DCR.0000000000002197](#)
- [Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant \(chemo\)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. *J Clin Oncol.* 2019;37\(1\):33-43. doi:10.1200/JCO.18.00032](#)
- ★ [Schaap DP, Boogerd LSF, Konishi T, et al. Rectal cancer lateral lymph nodes: multicentre study of the impact of obturator and internal iliac nodes on oncological outcomes. *Br J Surg.* 2021;108\(2\):205-213. doi:10.1093/bjs/znaa009](#)

Retroperitoneal Sarcoma

- [Callegaro D, Barretta F, Swallow CJ, et al. Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. *Eur J Cancer.* 2021;157:291-300. doi:10.1016/j.ejca.2021.08.008](#)
- [Nessim C, Raut CP, Callegaro D, et al. Analysis of differentiation changes and outcomes at time of first recurrence of retroperitoneal liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group \(TARPSWG\). *Ann Surg Oncol.* 2021;28\(12\):7854-7863. doi:10.1245/s10434-021-10024-y](#)
- ★ [Raut CP, Callegaro D, Miceli R, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. *Clin Cancer Res.* 2019;25\(8\):2664-2671. doi:10.1158/1078-0432.CCR-18-2700](#)

Serous Cystadenoma

- [Aziz H, Acher AW, Krishna SG, Cloyd JM, Pawlik TM. Comparison of society guidelines for the management and surveillance of pancreatic cysts: a review. *JAMA Surg.* 2022;157\(8\):723-730. doi:10.1001/jamasurg.2022.2232](#)



2024 Complex General Surgical Oncology

All References



- ★ [Scholten L, van Huijgevoort NCM, van Hooft JE, Besselink MG, Del Chiaro M. Pancreatic cystic neoplasms: different types, different management, new guidelines. *Visc Med.* 2018;34\(3\):173-177. doi:10.1159/000489641](#)

Squamous Cell Carcinoma

- ★ [Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology clinical practice guideline. *Pract Radiat Oncol.* 2020;10\(1\):8-20. doi:10.1016/j.ppro.2019.10.014](#)

Thyroid Cancer

- ★ [Haddad RI, Bischoff L, Ball D, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2022;20\(8\):925-951. doi:10.6004/jnccn.2022.0040](#)